JFG
ACRS icon

Jefferies Financial Group’s Aclaris Therapeutics ACRS Stock Holding History

Jefferies Financial Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$58.2K Hold
11,000
– – ﹤0.01% 1566
2026
Q1 		$41.3K Sell
11,000
-2
-0% -$7 ﹤0.01% 1653
2025
Q4 		$33.1K Buy
11,002
+2
+0% +$5 ﹤0.01% 1785
2025
Q3 		$20.9K Hold
11,000
– – ﹤0.01% 1411
2025
Q2 		$15.6K Sell
11,000
-29,200
-73% -$39.5K ﹤0.01% 1229
2025
Q1 		$61.5K Sell
40,200
-500
-1% -$1.07K ﹤0.01% 1509
2024
Q4 		$101K Buy
40,700
+29,200
+254% +$72.7K ﹤0.01% 1456
2024
Q3 		$13.2K Hold
11,500
– – ﹤0.01% 1379
2024
Q2 		$12.7K Hold
11,500
– – ﹤0.01% 1354
2024
Q1 		$14.3K Hold
11,500
– – ﹤0.01% 1534
2023
Q4 		$12.1K Sell
11,500
-25,051
-69% -$76.4K ﹤0.01% 1622
2023
Q3 		$250K Buy
36,551
+10,000
+38% +$85.5K ﹤0.01% 1280
2023
Q2 		$275K Sell
26,551
-390,000
-94% -$3.53M ﹤0.01% 1351
2023
Q1 		$3.37M Buy
+416,551
New +$5.29M 0.03% 484

Other funds holding ACRS

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Jefferies Financial Group's ACRS Position: Q2 2026 in Review

Jefferies Financial Group held its Aclaris Therapeutics (ACRS) position steady in Q2 2026 at 11,000 shares worth $58.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1566.

Jefferies Financial Group first reported a position in ACRS in Q1 2023 and has held it in 14 quarters since. The position peaked at $3.37M in Q1 2023. 148 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

  • Jefferies Financial Group held 11,000 shares of Aclaris Therapeutics worth $58.2K as of Q2 2026.
  • Jefferies Financial Group left its Aclaris Therapeutics share count unchanged in Q2 2026.
  • Aclaris Therapeutics made up ﹤0.01% of Jefferies Financial Group's portfolio in Q2 2026, its #1566 holding.
  • Jefferies Financial Group first reported a position in Aclaris Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Jefferies Financial Group's Aclaris Therapeutics position peaked at $3.37M in Q1 2023.
  • 148 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.